Last reviewed · How we verify
TEDISAMIL — Competitive Intelligence Brief
phase 3
tedisamil
Potassium voltage-gated channel subfamily A member 7
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
TEDISAMIL (TEDISAMIL). Tedisamil works by blocking certain potassium channels in the heart, which helps to regulate the heartbeat and prevent abnormal rhythms.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TEDISAMIL TARGET | TEDISAMIL | phase 3 | tedisamil | Potassium voltage-gated channel subfamily A member 7 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (tedisamil class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TEDISAMIL CI watch — RSS
- TEDISAMIL CI watch — Atom
- TEDISAMIL CI watch — JSON
- TEDISAMIL alone — RSS
- Whole tedisamil class — RSS
Cite this brief
Drug Landscape (2026). TEDISAMIL — Competitive Intelligence Brief. https://druglandscape.com/ci/tedisamil. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing